Business Wire

Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health

20.1.2026 14:00:00 CET | Business Wire | Press Release

Share

Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/

“At Colgate-Palmolive, we are driven by our purpose to reimagine a healthier future for all – and to make more smiles. We’re launching this collaboration with the WHO Foundation given its unique position to support global health challenges and Colgate’s leadership position in oral health as the brand that’s in more homes than any other,2” said Ram Raghavan, President, Enterprise Oral Care, Colgate-Palmolive. “Oral health is a critical – and too often overlooked – part of the global health agenda. We are committed to elevating oral health as a public health priority by scaling prevention and education and supporting evidence-based solutions that help strengthen health systems and improve lives across communities around the world.”

Oral health is foundational to overall health and wellbeing, yet remains underprioritized in many health systems. This neglect is exacerbated by factors such as economic status, education, health literacy, and access to healthcare.1 For children in particular, the consequences of poor oral health can lead to physical pain, emotional issues and challenges in education, including concentration difficulties and increased absenteeism.3-5 Through this collaboration, Colgate, part of the Colgate-Palmolive family of brands, and the WHO Foundation are supporting the World Health Organization to address persistent barriers affecting approximately half the world’s population, supporting efforts to integrate oral health into broader public health agendas and systems.

“The WHO Foundation supports WHO’s mission by mobilizing private funding in support of public health priorities,” said Anil Soni, Chief Executive Officer of the WHO Foundation. “Oral health plays an essential role in overall health, and progress depends on long-term investment in prevention, trusted guidance, and strong health systems. Support like this helps enable WHO’s work to advance oral health and improve health outcomes for communities around the world.”

A Shared Focus on System-Level Impact

The partnership aims to accelerate progress by elevating oral health as a foundational public health priority, guided by three strategic areas of action:

  • Scaling Oral Health Education: Helping to integrate core prevention and education principles into established government health infrastructure – such as school health systems – in designated regions.

  • Supporting Policy and Guidance: Supporting essential research to help Ministries of Health develop evidence-based, cost-effective recommendations for integrating oral health interventions into national health systems.

  • Increasing Prioritization: Supporting awareness through strategic, global, and cross-sector engagement to raise the profile of oral health and showcase the impact and outcomes of this partnership.

Colgate and the WHO Foundation are launching this partnership at a time when collaboration between public and private sectors is crucial to deliver progress against global health goals. At the recent Fourth United Nations High-Level Meeting, oral health was recognized and included as a public health priority in the prevention and control of noncommunicable diseases, with Member States supporting and calling for action. By focusing on preventive oral health measures, evidence-based policy, and broader public awareness about the link between oral health and overall health and wellbeing, this partnership seeks to improve lives around the world.

About Colgate-Palmolive Company

Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet and Prime100. We are recognized for our leadership and innovation in promoting sustainability and community wellbeing, including our achievements in decreasing plastic waste and promoting recyclability, saving water, conserving natural resources and improving children’s oral health through the Colgate Bright Smiles, Bright Futures program, which has reached approximately 2 billion children and their families since 1991. For more information about Colgate’s global business and how we are building a future to smile about, visit www.colgatepalmolive.com.

About the WHO Foundation

The WHO Foundation is an independent organization headquartered in Geneva, Switzerland, created in 2020 to support the mission of the World Health Organization. It mobilizes philanthropic capital and builds catalytic partnerships to advance health equity, respond to urgent health challenges, and strengthen systems that save lives. By connecting partners and practitioners, the Foundation helps scale trusted solutions, fund life-saving responses, and drive lasting change toward Health for All. who.foundation

References

  1. World Health Organization. “Oral health”. 17 March 2025, https://www.who.int/news-room/fact-sheets/detail/oral-health
  2. Worldpanel by Numerator. Brand footprint 2025: winning the 50:50 game. https://reports.worldpanelbynumerator.com/story/brand-footprint-2025-p/page/3/2. Published 2025.
  3. Dörfer, C, et al. The Relationship of Oral Health with General Health and NCDs: A Brief Review. Int Dent J. 2017.
  4. Kisely S. No Mental Health without Oral Health. Can J Psychiatry. 2016.
  5. Centers for Disease Control and Prevention. Oral Health Fast Facts. Accessed August 18, 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120050760/en/

Contacts

Samantha Ruijgh
Real Chemistry
(801) 971-5773
swapner@realchemistry.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release

Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release

SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release

Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye